Medera CEO Ronald Li & Keen Vision CEO and Chairman Kenneth Wong

Innovation in gene therapies is hard, but also potentially
ground-breaking and biotechnology firm Medera is taking its
decades-long journey in the space to the public markets just as
hits its next steps in the clinical process.


This week, we speak with Ronald Li, CEO of Medera, and Kenneth
Wong, CEO and Chairman of Keen Vision Acquisition Corp. The
two announced a $622 million dollar combination in September.


Ron explains how Medera has leveraged years of innovations
including the capacity to grow miniature human hearts for testing
as it advances gene therapies for heart failure that do not rely
on animal testing and could prove significantly cheaper than
alternatives.


Kenneth tells us why he believes those details align well with
the changing regulatory and investment climate around drug
development. And, why he views Medera as being a more mature
investment play in the biotech space than many of the others
coming to market today.